Connect Biopharma Holdings Ltd ADR (CNTB)

$2.69 -0.11 (-3.93%)
Market Cap 150.38M
Revenue (ttm) 26.03M
Net Income (ttm) -15.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60.05%
Debt to Equity Ratio 0.00
Volume 66,800
Avg Vol 97,234
Day's Range N/A - N/A
Shares Out 55.90M
Stochastic %K 48%
Beta -0.20
Analysts Strong Sell
Price Target $7.90

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1040
Address:
3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States
Maissessap
Maissessap Mar. 15 at 10:17 AM
$CNTB Things are moving: https://finance.yahoo.com/news/connect-biopharma-touts-next-gen-141541140.html
0 · Reply
BOUDIN420
BOUDIN420 Mar. 13 at 11:58 PM
$CNTB nice little dip to fill the fvg and reset the chart
0 · Reply
JoshThe3rd
JoshThe3rd Mar. 13 at 4:47 PM
$CNTB @Doozio we got a sexy weekly base here
0 · Reply
cheating_stock_investor
cheating_stock_investor Mar. 13 at 3:28 PM
$HRTX any barry quart fans left here at the heron board come check out $CNTB Hes gonna bring this double digits shortly.
0 · Reply
BOUDIN420
BOUDIN420 Mar. 12 at 11:18 PM
$CNTB Late Breaking phase 3 results will be presented on the 28th at 2026 AAD Meeting
0 · Reply
TheWings977
TheWings977 Mar. 10 at 2:58 PM
$CNTB keep moving baby!!!
0 · Reply
mikeywo
mikeywo Mar. 10 at 12:37 PM
$CNTB Barry does a nice job on these investment conferences making things understandable to retail and the investment community. There is no denying the data coming out from this drug and this is Barry’s swan song and he wants to go into retirement with a big check when connect is bought out by this time next year.
0 · Reply
cheating_stock_investor
cheating_stock_investor Mar. 10 at 1:49 AM
$CNTB barry will turn this around like he did $HRTX when appa was pennies lol
1 · Reply
jdkd4
jdkd4 Mar. 4 at 3:52 PM
$CNTB looking good!!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 9:32 PM
$CNTB RSI: 44.30, MACD: 0.0076 Vol: 0.17, MA20: 2.59, MA50: 2.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on CNTB
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 10, 2026, 9:00 AM EDT - 5 days ago

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 9:00 AM EST - 12 days ago

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 9:00 AM EST - 24 days ago

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

Jan 12, 2026, 8:00 AM EST - 2 months ago

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 9:00 AM EST - 3 months ago

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 4 months ago

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Nov 3, 2025, 9:36 PM EST - 4 months ago

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Sep 29, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Aug 27, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Aug 14, 2025, 8:00 AM EDT - 7 months ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 22, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 21, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 18, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 17, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 13, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 28, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 20, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 14, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

May 13, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 24, 2025, 9:00 AM EDT - 11 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Apr 1, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 31, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 28, 2025, 4:05 PM EDT - 1 year ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Present at Two Upcoming Investor Conferences

Mar 3, 2025, 8:00 AM EST - 1 year ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Attovia Therapeutics Appoints Chief Financial Officer

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Attovia Therapeutics Appoints Chief Financial Officer

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 9, 2024, 3:55 PM EDT - 1 year ago

CNTB Stock Dips Amid Biotech Sector Volatility

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Oct 2, 2024, 4:14 PM EDT - 1 year ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 2 years ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Apr 16, 2024, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Feb 12, 2024, 4:30 PM EST - 2 years ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 12, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Dec 11, 2023, 4:05 PM EST - 2 years ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:03 AM EST - 2 years ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 21, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Nov 20, 2023, 4:41 PM EST - 2 years ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 4:15 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Sep 12, 2023, 6:00 AM EDT - 2 years ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Participate in Upcoming September Investor Conferences

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Maissessap
Maissessap Mar. 15 at 10:17 AM
$CNTB Things are moving: https://finance.yahoo.com/news/connect-biopharma-touts-next-gen-141541140.html
0 · Reply
BOUDIN420
BOUDIN420 Mar. 13 at 11:58 PM
$CNTB nice little dip to fill the fvg and reset the chart
0 · Reply
JoshThe3rd
JoshThe3rd Mar. 13 at 4:47 PM
$CNTB @Doozio we got a sexy weekly base here
0 · Reply
cheating_stock_investor
cheating_stock_investor Mar. 13 at 3:28 PM
$HRTX any barry quart fans left here at the heron board come check out $CNTB Hes gonna bring this double digits shortly.
0 · Reply
BOUDIN420
BOUDIN420 Mar. 12 at 11:18 PM
$CNTB Late Breaking phase 3 results will be presented on the 28th at 2026 AAD Meeting
0 · Reply
TheWings977
TheWings977 Mar. 10 at 2:58 PM
$CNTB keep moving baby!!!
0 · Reply
mikeywo
mikeywo Mar. 10 at 12:37 PM
$CNTB Barry does a nice job on these investment conferences making things understandable to retail and the investment community. There is no denying the data coming out from this drug and this is Barry’s swan song and he wants to go into retirement with a big check when connect is bought out by this time next year.
0 · Reply
cheating_stock_investor
cheating_stock_investor Mar. 10 at 1:49 AM
$CNTB barry will turn this around like he did $HRTX when appa was pennies lol
1 · Reply
jdkd4
jdkd4 Mar. 4 at 3:52 PM
$CNTB looking good!!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 9:32 PM
$CNTB RSI: 44.30, MACD: 0.0076 Vol: 0.17, MA20: 2.59, MA50: 2.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 11:32 PM
$CNTB Current Stock Price: $2.67 Contracts to trade: $2.5 CNTB Feb 20 2026 Call Entry: $0.48 Exit: $0.87 ROI: 81% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ReturnStacking
ReturnStacking Feb. 20 at 1:29 PM
$CNTB Centessa Pharmaceuticals develops immunology and oncology assets. Valuation is driven by clinical milestones. Portfolio diversification reduces single-asset risk.
0 · Reply
topstockalerts
topstockalerts Feb. 17 at 8:24 PM
$CNTB Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.
0 · Reply
BioCurious1
BioCurious1 Feb. 17 at 6:37 PM
$CNTB gonna be a big first half in 2026 with P1b data coming in the next few weeks Paired with the Phaee 2 Trial Data mid year. Low visibility currently , curious to see how it develops over the next few months. Hoping for an 100% gain here
1 · Reply
PortfolioOverture
PortfolioOverture Feb. 17 at 2:24 PM
$CNTB Connect Biopharma advancing rademikibart for asthma/COPD with unique MOA data; Phase 1b results expected Q1 2026 and Seabreeze studies mid-2026; cash runway into 2027.
0 · Reply
ScalperZed
ScalperZed Feb. 17 at 8:53 AM
$CNTB Pre-revenue biotech; early-stage
0 · Reply
BioCurious1
BioCurious1 Feb. 11 at 5:37 PM
$CNTB 10 day vol average has been super low. 60k-70k shares being traded. Set for a big move when this reports mid year, potentially earlier with phase 1b results coming in the next few weeks. Personally bullish, but going to be a big move one way or the other
0 · Reply
BioCurious1
BioCurious1 Feb. 6 at 3:30 PM
$CNTB this is going to fly or tank depending on the news. When I bought shares it legit moved the price 5%. I’ve never seen something move so fragile with a purchase under 25k
2 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 1:49 PM
$CNTB Excellent article that nails exactly where CNTB stands right now. So if you want to update your CNTB knowledge or get acquainted with CNTB, this is a must read. https://everyticker.com/quote/CNTB/analysis/connect-biopharma-betting-on-rademikibart-s-acute-respiratory-potential-cntb
0 · Reply
BioCurious1
BioCurious1 Feb. 2 at 9:13 PM
$SGMT and $CNTB prob some of the best bio plays in 2026
2 · Reply
Finanz
Finanz Jan. 29 at 6:37 PM
$CNTB Chart
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 1:00 AM
$CNTB Current Stock Price: $2.27 Contracts to trade: $5 CNTB Jan 16 2026 Call Entry: $0.09 Exit: $0.13 ROI: 48% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply